Fuhong Hanlin and Yisheng Biotech have collaboratively submitted an application for the marketing authorization of Bevacizumab Intravitreal Injection (HLX04-O). This injection, a humanized monoclonal antibody targeting VEGF, aims to curtail neovascularization by inhibiting the VEGF signaling pathway, effectively treating ocular conditions such as wet age-related macular degeneration (wAMD). In Phase III clinical trials, HLX04-O has demonstrated efficacy on par with Ranibizumab, while maintaining a favorable safety profile. The drug is currently undergoing international, multicenter Phase III clinical trials spanning China, Australia, the European Union, the United States, and other regions. wAMD is a leading cause of blindness in the elderly population, and anti-VEGF therapies have emerged as the gold standard for its treatment. The development of HLX04-O is poised to significantly address an unmet clinical need.